Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more
Whanin Pharm (016580) - Total Liabilities
Latest total liabilities as of September 2025: ₩47.06 Billion KRW
Based on the latest financial reports, Whanin Pharm (016580) has total liabilities worth ₩47.06 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Whanin Pharm - Total Liabilities Trend (2009–2024)
This chart illustrates how Whanin Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Whanin Pharm Competitors by Total Liabilities
The table below lists competitors of Whanin Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
mPLUS Corp
KQ:259630
|
Korea | ₩149.67 Billion |
|
Hindware Home Innovation Limited
NSE:HINDWAREAP
|
India | ₹17.69 Billion |
|
Ensurge Micropower ASA
OTCQB:ENMPF
|
USA | $12.92 Million |
|
CYGAM Energy Inc.
V:CYG
|
Canada | CA$7.41 Million |
|
Malayan Flour Mills Bhd
KLSE:3662
|
Malaysia | RM922.77 Million |
|
Nordic Mining ASA
OL:NOM
|
Norway | Nkr2.32 Billion |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
USA | $222.87 Million |
|
Ching Feng Home Fashions Co Ltd
TW:9935
|
Taiwan | NT$5.19 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Whanin Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Whanin Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Whanin Pharm (2009–2024)
The table below shows the annual total liabilities of Whanin Pharm from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩48.70 Billion | +13.22% |
| 2023-12-31 | ₩43.02 Billion | +21.36% |
| 2022-12-31 | ₩35.45 Billion | -1.44% |
| 2021-12-31 | ₩35.96 Billion | +9.12% |
| 2020-12-31 | ₩32.96 Billion | +8.33% |
| 2019-12-31 | ₩30.42 Billion | +8.26% |
| 2018-12-31 | ₩28.10 Billion | -11.50% |
| 2017-12-31 | ₩31.75 Billion | +36.22% |
| 2016-12-31 | ₩23.31 Billion | +23.35% |
| 2012-12-31 | ₩18.90 Billion | +16.26% |
| 2011-12-31 | ₩16.25 Billion | +54.67% |
| 2009-12-31 | ₩10.51 Billion | -- |